Immunome Inc. (IMNM): M&A transaction — Immunome acquires full ownership of ROR1 ADC assets from Zentalis for 1.8M shares plus $5M milestone

Immunome Inc.

Issued 1,805,502 shares of common stock to Zentalis as partial consideration for the asset purchase.
Obligated to pay $5M cash upon achievement of a developmental milestone; prior License Agreement terminated.
Standstill restrictions on Zentalis for one year; lockup on selling >50% of shares for six months.
Immunome to file resale registration statement within 30 days for shares issued to Zentalis.
Asset purchase includes ROR1 antibody-drug conjugate platform and related intellectual property.

item 1.01 item 1.02 item 2.01 item 3.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Immunome Inc. completed an acquisition involving Zentalis Pharmaceuticals, Inc. for 1,805,502 shares of Company common stock (closed 2024-10-25).

Action: acquisition
Counterparty: Zentalis Pharmaceuticals, Inc.
Consideration: 1,805,502 shares of Company common stock
Closing: 2024-10-25

Exact text from the filing

the customary rights and obligations of a sole owner (the “Asset Purchase”). Under the Purchase Agreement, in consideration of the Asset Purchase, the Company issued to Zentalis 1,805,502 shares of Company common stock (the “Shares”), described below under Stock Issuance Agreement . The Company is also obligated to pay Zentalis a one-time payment of $5,000,000 in

View on SEC.gov

21 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Immunome Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-112053

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.